ADHD drugs and cardiovascular risk.
Nissen
Steven E
SE
Department of Cardiovascular Medicine at the Cleveland Clinic, Cleveland, USA.
D000328:Adult; D001067:Appetite Depressants / Q000009:adverse effects; D001289:Attention Deficit Disorder with Hyperactivity / Q000188:drug therapy*; D002318:Cardiovascular Diseases / Q000139:chemically induced*; D000697:Central Nervous System Stimulants / Q000009:adverse effects* / Q000627:therapeutic use; D002648:Child; D003645:Death, Sudden / Q000209:etiology; D004335:Drug and Narcotic Control; D029789:Ephedra / Q000009:adverse effects; D005260:Female; D006801:Humans; D008297:Male; D010665:Phenylpropanolamine / Q000009:adverse effects; D013566:Sympathomimetics / Q000009:adverse effects* / Q000737:chemistry; D014481:United States; D014486:United States Food and Drug Administration
D001067:Appetite Depressants; D000697:Central Nervous System Stimulants; D013566:Sympathomimetics; D010665:Phenylpropanolamine